31 August 2018
An updated report by visiongain, released in September 2016, forecasts that revenue from cardiovascular medical devices will more than double from 2015 to 2026. That investigation predicts the cardiovascular devices market will achieve overall sales of $63.4bn in 2020, with further revenue growth expected. Growth variations between the segments are expected to occur from 2016 to 2026, with the new study’s purpose to show that market and its components’ technological and commercial prospects from 2016.
Those predictions and others appear in Cardiovascular Medical Devices Market and Forecasts 2016-2026: Analysing Cardiac Rhythm Management, Prosthetics, Interventional Cardiology, Heart Monitoring and Diagnostics, also Assessing Pacemakers, Defibrillators, Ventricular Assist Products, Stents, Artificial Heart Valves, Catheters, Angioplasty Balloons, Guidewires, Electrocardiography, Cardio Output Monitoring and Accessories, Covering the US, Japan, China, India, Brazil, Russia and Europe (EU5). Visiongain is a business information publisher and consultancy in London, UK. Its purpose is helping companies and other organisations assess the future of industries and markets in healthcare and other fields.
The updated study’s author said: “The cardiovascular medical devices market is relatively mature in Western countries, but there is still significant room for growth in developing economies. There is a high rate of innovation in both technology and design in the market, and the introduction of new devices will continue to drive market expansion. The relatively sluggish growth of the global economy and government restrictions on reimbursement will constrain growth opportunities in developed nations, but in developing economies, the increasing prosperity of individuals, the ageing of the population and the continuing trend towards adopting a Western diet and lifestyle will all drive an increase in cardiovascular disease, and hence a rising demand for medical devices.”
Mergers and acquisitions occurred this decade, showing that medical device industry’s move towards consolidation, with expansion of its market. Those products rise in prominence. Cardiac device manufacturers compete to launch novel technologies with proven cost-effectiveness, aiming to improve treatment and management of heart conditions and other cardiovascular diseases. That industry’s research and development shows great promise to benefit patients, healthcare providers and companies from 2016 to 2026.
Visiongain’s new report shows overall world revenue for that market to 2026. It also gives revenue predictions from 2016 to 2026 at world level for four main segments:
• Cardiac rhythm management
• Prosthetic devices
• Interventional cardio products
• Monitoring and diagnostics.
That work also shows world-level revenue forecasts to 2026 for another 11 applications:
• Cardiac pacemakers
• Ventricular assist devices
• Cardiac stents
• Heart valves
• Angioplasty balloons
• Cardiac output monitoring products.
Visiongain’s industry analysis also gives sales forecasts from 2016 to 2026 for the US, Japan, Germany, France, the UK, Italy, Spain, China, India, Russia and Brazil. The study’s forecasting comes with discussions, including SWOT and STEP analyses. That investigation includes profiles of leading companies – Medtronic, St. Jude Medical, Boston Scientific, Biotronik, Abbott, Johnson & Johnson, Edwards Lifesciences, Terumo, LivaNova, CR Bard and Integer Holdings – discussing activities, products, results, deals and outlooks.
Cardiovascular Medical Devices Market and Forecasts 2016-2026 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, medical devices, diagnostics, biotechnologies and outsourced services. Each year updated and new studies appear there, with the purpose of helping readers assess established and emerging markets’ potentials.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.